Addex Company announced that its newest mGluR2 PAM, ADX71149 demonstrated safety and tolerance in healthy men and women, and it passed IIa of clinical trial being efficient in patients with negative schizophrenia symptoms [106,107]. The gene discussed is GRM2; the disease is schizophrenia.